LUMO lumos-pharma.com Earnings growth forecast for next year

Corporate emblem and logo of Lumos Pharma (LUMO)

Lumos Pharma, Inc. (LUMO) is mitigating clinical risks by diversifying its platform for rare endocrine pathologies, establishing a foundation for the introduction of convenient oral treatments for growth hormone deficiency. The projected EPS growth rate for next year visualizes these expectations, where 45.70 reflects the latest metric value. The strategy relies on scientific alliances with academic institutions to develop pediatric medications.

Lumos Pharma Corp (LUMO): Expected net earnings per share growth next year from 07/04/2022 to 12/21/2024

LUMO (Lumos Pharma Inc): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:LUMO, lumos-pharma.com
Finished products of Lumos Pharma

Lumos Pharma, Inc. (LUMO) has a limited ability to withstand market volatility due to its dependence on the outcome of clinical trials for a single hormone deficiency therapy drug. The trend in market expectations for EPS growth reflects the discounting of future cash flows under tight monetary policy, where any changes to consensus earnings forecasts directly adjust the fundamental value of this speculative biotech asset.

Analysis of competing companies

ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (Rhythm Pharma)|Net earnings per share growth forecast for next year akerotx.com AKRO|Metsera Therapeutics (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|CRNX: Net earnings per share growth forecast for next year|NAMS: Earnings growth forecast for next year|SLNO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Amicus Corp|89bio Pharma (ETNB) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year agios.com (AGIO)|Expected earnings per share growth for next year structuretx.com GPCR|Net earnings per share growth forecast for next year MiMedx Group Inc MDXG|Expected earnings per share trend next year RZLT|lexpharma.com - Earnings growth forecast for next year|MBX (MBX Biosciences Inc) - Projected earnings per share growth rate for next year|ALT: Earnings growth forecast for next year|Aardvark Therapeutics Inc - Expected earnings per share trend next year|SGMT (Sagimet Biosciences, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year BioAge|Earnings growth forecast for next year BMEA|Expected earnings per share growth for next year Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. - Expected earnings per share growth for next year|Expected earnings per share trend next year VTVT|Agape ATP Corporation - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Pluri PLUR|SYBX: Earnings growth forecast for next year|Expected net earnings per share growth next year Lipocine Inc. (LPCN)|MTNB (Matinas BioPharma) - Earnings growth forecast for next year|sprucebiosciences.com (SPRB) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Galecto Corp (GLTO)|CTCX - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year